M. Rudek

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
M A Rudek, M. A. Rudek, Michelle A Rudek, M. Rudek, M.a. Rudek, Michelle Rudek, Michelle A. Rudek, M Rudek
Publication record
302 papers · 10,758 citations · H-index 56

PAPERS

A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
202513 citationsauthor #8
5‐YEAR UPDATE ON FRONTLINE BRENTUXIMAB VEDOTIN WITH AVD FOR STAGE II‐IV HIV‐ASSOCIATED CLASSICAL HODGKIN LYMPHOMA (AMC‐085)
20250 citationsauthor #3
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
20253 citationsauthor #5
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
20256 citationsauthor #5
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma
20240 citationsauthor #5
Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer
20241 citationsauthor #5
Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance
20241 citationsauthor #21
Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma.
20248 citationsauthor #15
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial
202437 citationsauthor #20
Assay for the quantification of abemaciclib, its metabolites, and olaparib in human plasma by liquid chromatography-tandem mass spectrometry.
20240 citationsauthor #4
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
20245 citationsauthor #3
Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.
20230 citationsauthor #10
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
202317 citationsauthor #3
Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
20231 citationsauthor #6
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
202311 citationsauthor #8
DNA methyltransferase inhibitor exposure–response: Challenges and opportunities
202325 citationsauthor #7
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor.
20234 citationsauthor #5
DPYD Testing: Time to Put Patient Safety First.
202326 citationsauthor #17
ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative
20230 citationsauthor #8
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
202317 citationsauthor #5
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus–positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
20234 citationsauthor #2
Six-month effective treatment of corneal graft rejection
202316 citationsauthor #13
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs
202313 citationsauthor #5
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor
20233 citationsauthor #10
Phase I trial of the multi-kinase inhibitor cabozantinib, a CYP3A4 substrate, plus CYP3A4 interacting antiretroviral therapy in people living HIV and cancer (AMC087).
20232 citationsauthor #11
Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice
202321 citationsauthor #14
Serum concentrations of losartan metabolites correlate with improved physical function in a pilot study of prefrail older adults.
20225 citationsauthor #23
A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology
20226 citationsauthor #6
CTNI-26. SURGICAL WINDOW OF OPPORTUNITY TRIAL OF NAVTEMADLIN (KRT 232; AMG232) IN PATIENTS WITH RECURRENT GLIOBLASTOMA
20221 citationsauthor #2
Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study
20220 citationsauthor #6
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
202279 citationsauthor #13
CTNI-60. PRELIMINARY RESULTS OF BINIMETINIB AND ENCORAFENIB IN ADULTS WITH RECURRENT BRAF V600E-MUTATED HIGH-GRADE GLIOMA
20225 citationsauthor #8
Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography tandem mass spectrometry.
20222 citationsauthor #9
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax.
20221 citationsauthor #7
Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials.
20221 citationsauthor #3
Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity
20229 citationsauthor #7
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)
202124 citationsauthor #14
964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)
20213 citationsauthor #13
Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry.
20211 citationsauthor #5
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.
202118 citationsauthor #10
Quantitation of Cabozantinib in Human Plasma by LC-MS/MS.
20211 citationsauthor #4
Correction to: Clonidine for sedation in infants during therapeutic hypothermia with neonatal encephalopathy: pilot study
20210 citationsauthor #5
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
20218 citationsauthor #8
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax.
20213 citationsauthor #7
Clonidine for sedation in infants during therapeutic hypothermia with neonatal encephalopathy: pilot study
20216 citationsauthor #5
Validation of a rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of vistusertib.
20212 citationsauthor #5
The 1994 National Cancer Institute’s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.
20210 citationsauthor #10
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review.
202113 citationsauthor #5
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
20205 citationsauthor #21
Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids
202016 citationsauthor #9
Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial
202032 citationsauthor #16
Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery.
202027 citationsauthor #3
Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer
202010 citationsauthor #10
A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation.
202035 citationsauthor #2
Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen
20200 citationsauthor #7
Successful gene therapy requires targeting the vast majority of cancer cells
20202 citationsauthor #6
For HIPEC, synergistic effects of hyperthermia and doxorubicin are optimal when simultaneously combined
20200 citationsauthor #2
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
202011 citationsauthor #2
Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
20207 citationsauthor #10
A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
202033 citationsauthor #11
Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma
201913 citationsauthor #17
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
201917 citationsauthor #15
Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia
201924 citationsauthor #11
A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors
201924 citationsauthor #10
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
20198 citationsauthor #6
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
201945 citationsauthor #24
MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).
20198 citationsauthor #4
Establishing an investigational drugs and research residency at an academic medical center.
20194 citationsauthor #5
A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
201918 citationsauthor #6
Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment
20199 citationsauthor #3
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer
201831 citationsauthor #6
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
201889 citationsauthor #23
Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias
20188 citationsauthor #11
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer
201825 citationsauthor #9
The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma
201858 citationsauthor #12
The HDAC3–SMARCA4–miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
201865 citationsauthor #14
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
2018204 citationsauthor #28
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure‐FLT3 Relationship
201823 citationsauthor #9
Targeting the hedgehog pathway in esophageal adenocarcinoma (EAC) using Itraconazole.
20182 citationsauthor #16
Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034
201829 citationsauthor #4
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)
201816 citationsauthor #3
Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies
20177 citationsauthor #8
SCDT-44. CLINICAL EVALUATION OF REGADENOSON AS A PHARMACOLOGIC AGENT TO TRANSIENTLY MODIFY BLOOD-BRAIN BARRIER INTEGRITY TO FACILITATE ENTRY OF CHEMOTHERAPY INTO BRAIN PARENCHYMA
20170 citationsauthor #2
Irinotecan-eluting LC Bead-M1 (DEBIRI-M1) for patients with liver metastases from colorectal cancer: a phase II single-center study
20170 citationsauthor #5
Tolerability of paclitaxel/carboplatin (PCb) in solid tumor patients (pts) infected with HIV.
20171 citationsauthor #7
A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
201723 citationsauthor #14
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy
201726 citationsauthor #18
A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer.
20172 citationsauthor #18
ACTR-85. THE EFFECT OF REGADENOSON ON TEMOZOLOMIDE NEUROPHARMACOKINETICS IN GLIOBLASTOMA PATIENTS MEASURED BY INTRACEREBRAL MICRODIALYSIS
20170 citationsauthor #15
Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
20178 citationsauthor #8
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
201746 citationsauthor #21
Exposure–ResponseofVeliparib to InformPhase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
20170 citationsauthor #9
An open-label expanded-access study to evaluate the safety, tolerability, and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and hepatic impairment.
20170 citationsauthor #3
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.
2017130 citationsauthor #3
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma
201724 citationsauthor #3
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
201736 citationsauthor #5
Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
20174 citationsauthor #9
Entinostat: a promising treatment option for patients with advanced breast cancer.
2017121 citationsauthor #2
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
201661 citationsauthor #19
Effect of simvastatin on the pharmacokinetics of anastrozole
20160 citationsauthor #6

TIMELINE

1999 2 citations

2000 128 citations

2001 218 citations

2002 318 citations

2003 133 citations

2004 99 citations

2005 344 citations

2006 503 citations

2007 88 citations

2008 376 citations

2009 377 citations

2010 1,042 citations

2011 1,798 citations

2012 638 citations

2013 998 citations

2014 977 citations

2015 501 citations

2016 484 citations

2017 428 citations

2018 550 citations

2019 170 citations

2020 178 citations

2021 79 citations

2022 109 citations

2023 160 citations

2024 52 citations

2025 22 citations

Unknown 1 citations

M. Rudek

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT